Articles tagged with: Aplidin
Headline, News »
A Phase 2 clinical trial showed that plitidepsin alone had limited efficacy in heavily pretreated relapsed and refractory multiple myeloma patients. However, plitidepsin in combination with dexamethasone was effective enough to warrant further study. Plitidepsin alone or in combination with dexamethasone was well tolerated.
“Plitidepsin has not shown very significant efficacy when used in monotherapy,” explained Dr. María Mateos, the lead investigator of this study. “Nevertheless, in the present study we have seen some hints of activity in very heavily pretreated patients.”
Among the patients who received plitidepsin alone, 13…
News »
Myeloma Expert Dr. James R. Berenson To Field Questions At The Beacon Forums Next Week –Multiple myeloma patients will once again have the opportunity to get expert answers to their myeloma-related questions: Leading myeloma expert Dr. James R. Berenson, founder of the Institute for Myeloma & Bone Cancer Research, will answer medical questions posted to the Beacon’s multiple myeloma forums during the upcoming week. Readers are encouraged to begin posting their questions in the forums.
Potential Myeloma Treatment Mapatumumab Fails In Phase 2 Trials – Human Genome Sciences announced on Wednesday that results from a recent Phase 2 trial showed that mapatumumab (HGS-ETR1) in combination with Velcade (bortezomib) did not lead to better response rates or progression-free survival than Velcade alone. However, the treatment was well tolerated in trial participants. For more information, please see the Human Genome Sciences press release.
PharmaMar Initiates Phase 3 Myeloma Trial Of Plitidepsin – Spanish company PharmaMar on Tuesday announced the start of enrollment for an international Phase 3 trial of plitidepsin (proposed brand name: Aplidin) in relapsed/refractory multiple myeloma patients. The trial will enroll 300 patients and will test plitidepsin in combination with dexamethasone (Decadron) vs. dexamethasone alone. Plitidepsin is an antitumor agent of marine origin that is synthetically produced. For more information, please see the PharmaMar press release and the trial information at ClinicalTrials.gov.
News »
A recent paper published in Lancet Oncology examines drugs that target biological mechanisms in multiple myeloma. This article is the last of three articles discussing new drugs for myeloma treatment.
Cells have correction mechanisms that prevent deleterious proteins from aggregating. Blocking either of these systems leads to an accumulation of toxins proteins in the cell and results in cell death.
Heat-shock Protein Inhibitors
One system that responds to misfolded proteins is heat-shock proteins (HSP). Among their other functions, these proteins stabilize survival signaling proteins that are overexpressed in multiple myeloma.…
Resources, Treatments Under Development »
| Brand Name: | Aplidin |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | 3 |
